In many such patients, diazoxide is ineffective, resulting in the need for a trial of SRL to reduce excess insulin secretion, before resorting to irreversible sub-total pancreatectomy with consequent development of insulin dependent diabetes and exocrine pancreatic insufficiency. The gene discussed is INS; the disease is exocrine pancreatic insufficiency.